ArticleBioengineering (Basel, Switzerland)2025
DME-RWKV: An Interpretable Multimodal Deep Learning Framework for Predicting Anti-VEGF Response in Diabetic Macular Edema.
Article in Bioengineering (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Diabetic macular edema (DME) is a leading cause of vision loss, and predicting patients' response to anti-vascular endothelial growth factor (anti-VEGF) therapy remains a clinical challenge. In this study, we developed an interpretable deep learning model for treatment prediction and biomarker analysis. We retrospectively analyzed 402 eyes from 371 patients with DME. The proposed DME-Receptance Weighted Key Value (RWKV) integrates optical coherence tomography (OCT) and ultra-widefield (UWF) imaging using Causal Attention Learning (CAL), curriculum learning, and global completion (GC) loss to enhance microlesion detection and structural consistency. The model achieved a Dice coefficient of 71.91 ± 8.50% for OCT biomarker segmentation and an AUC of 84.36% for predicting anti-VEGF response, outperforming state-of-the-art methods. By mimicking clinical reasoning with multimodal integration, DME-RWKV demonstrated strong interpretability and robustness, providing a promising AI framework for precise and explainable prediction of anti-VEGF treatment outcomes in DME.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.